AstraZeneca Pharma India Limited — Important, 28-02-2025: Updates

AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation to import and distribute Durvalumab solution for infusion (Imfinzi) in India for an additional indication. This approval allows the use of Durvalumab, in combination with Tremelimumab, for treating patients with unresectable hepatocellular carcinoma (uHCC). The company is now positioned to market this solution, pending necessary statutory approvals. This development enhances AstraZeneca’s portfolio in oncology, potentially boosting its market presence and offering new treatment options for patients in India. Investors should watch closely for subsequent approvals that could influence the company's growth trajectory.